BR112018000097A2 - anticorpos humanizados - Google Patents

anticorpos humanizados

Info

Publication number
BR112018000097A2
BR112018000097A2 BR112018000097A BR112018000097A BR112018000097A2 BR 112018000097 A2 BR112018000097 A2 BR 112018000097A2 BR 112018000097 A BR112018000097 A BR 112018000097A BR 112018000097 A BR112018000097 A BR 112018000097A BR 112018000097 A2 BR112018000097 A2 BR 112018000097A2
Authority
BR
Brazil
Prior art keywords
amyloid
amyloidosis
humanized antibodies
peptide
n3pe
Prior art date
Application number
BR112018000097A
Other languages
English (en)
Inventor
Piechotta Anke
Rahfled Jens-Ulrich
Kleinschmidt Martin
Schilling Stephan
Gillies Steven
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of BR112018000097A2 publication Critical patent/BR112018000097A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)

Abstract

a invenção refere-se a anticorpos humanizados que se ligam a um epítopo no n-terminal de peptídeo amiloide beta piroglutamado (aß n3pe) e a tratamento preventivo e terapêutico de doenças e condições que são relacionadas à acumulação e deposição de peptídeos amiloide, tais como amiloidose, um grupo de distúrbios e anormalidades associados com peptídeo amiloide piroglutamado, como doença de alzheimer, síndrome de down, angiopatia amiloide cerebral e outros aspectos relacionados. mais especificamente, refere-se ao uso de anticorpos monoclonais humanizados para ligar peptídeo amiloide beta piroglutamado em plasma, cérebro e fluido cérebro-espinhal para prevenir a acumulação ou reverter a deposição de aß n3pe dentro do cérebro e em vários tecidos na periferia, e para aliviar amiloidose. a presente invenção ainda se refere a ensaios diagnósticos para o diagnóstico de amiloidose usando os anticorpos humanizados da invenção.
BR112018000097A 2015-07-16 2016-07-15 anticorpos humanizados BR112018000097A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193356P 2015-07-16 2015-07-16
US201562209650P 2015-08-25 2015-08-25
PCT/EP2016/066924 WO2017009459A2 (en) 2015-07-16 2016-07-15 Humanized antibodies

Publications (1)

Publication Number Publication Date
BR112018000097A2 true BR112018000097A2 (pt) 2018-09-04

Family

ID=56411667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000097A BR112018000097A2 (pt) 2015-07-16 2016-07-15 anticorpos humanizados

Country Status (14)

Country Link
US (2) US10603367B2 (pt)
EP (1) EP3322723A2 (pt)
JP (2) JP7002811B2 (pt)
KR (1) KR20180030653A (pt)
CN (1) CN108699139B (pt)
AU (1) AU2016293104B2 (pt)
BR (1) BR112018000097A2 (pt)
CA (1) CA2992386A1 (pt)
EA (1) EA038120B1 (pt)
IL (1) IL256579B2 (pt)
MX (1) MX2018000696A (pt)
NZ (1) NZ739181A (pt)
WO (1) WO2017009459A2 (pt)
ZA (1) ZA201800048B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
MX2021003867A (es) * 2018-10-04 2021-09-08 Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.
KR20210143858A (ko) * 2019-03-26 2021-11-29 얀센 파마슈티카 엔.브이. 피로글루타메이트 아밀로이드-β에 대한 항체 및 이의 용도
JP7299566B2 (ja) * 2019-07-05 2023-06-28 株式会社島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
EP4007773A1 (en) * 2019-08-06 2022-06-08 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
AR127498A1 (es) * 2021-10-28 2024-01-31 Abbvie Inc ANTICUERPOS ANTI-b AMILOIDE Y MÉTODOS DE USO DE LOS MISMOS
CN115354048B (zh) * 2022-06-08 2024-02-02 暨南大学 阿尔茨海默病动物模型的构建方法、用途和Aβ42重组表达载体
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0916366B1 (pt) * 2008-07-21 2021-08-10 Probiodrug Ag Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma
US20110002945A1 (en) * 2009-07-01 2011-01-06 O'nuallain Brian Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins
US9062101B2 (en) * 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2828433C (en) * 2011-03-16 2020-08-04 Probiodrug Ag Diagnostic antibody assay
US9499610B2 (en) * 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ

Also Published As

Publication number Publication date
IL256579B2 (en) 2023-03-01
EA201890313A1 (ru) 2018-09-28
US20180140689A1 (en) 2018-05-24
CA2992386A1 (en) 2017-01-19
WO2017009459A3 (en) 2017-03-16
CN108699139B (zh) 2022-06-24
WO2017009459A2 (en) 2017-01-19
JP2022017271A (ja) 2022-01-25
US10603367B2 (en) 2020-03-31
EP3322723A2 (en) 2018-05-23
IL256579B (en) 2022-11-01
AU2016293104B2 (en) 2022-08-11
AU2016293104A1 (en) 2018-02-08
US20200138922A1 (en) 2020-05-07
MX2018000696A (es) 2018-05-28
KR20180030653A (ko) 2018-03-23
NZ739181A (en) 2023-05-26
IL256579A (en) 2018-02-28
EA038120B1 (ru) 2021-07-08
US11045533B2 (en) 2021-06-29
JP7002811B2 (ja) 2022-03-04
JP2018524370A (ja) 2018-08-30
ZA201800048B (en) 2018-11-28
CN108699139A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
BR112018000097A2 (pt) anticorpos humanizados
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
BR112015007882A2 (pt) anticorpo monoclonal isolado que se liga a alfa sinucleína humana, ácido nucleico, composição farmacêutica e uso do anticorpo
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
CR20150016A (es) Anticuerpo monoclonal
WO2019098763A3 (ko) 알파-시누클레인에 대한 항체 및 그 용도
AR085198A1 (es) Composicion farmaceutica
MX356800B (es) Anticuerpo tau humanizado.
EA201892690A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
MX2016005050A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
BR112015013312A2 (pt) método para reduzir placas amiloides do cérebro usando anticorpos anti-abeta
CO6602134A2 (es) Proteinas de union a antigeno especificas para componente amiloide serico p
BR112016008275A2 (pt) Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
CO6640211A2 (es) Composiciones del péptido a-beta y métodos
BR112019000098A2 (pt) proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
BR112019000736A2 (pt) processo para preparação de composições de imunoglobulina
WO2017027685A3 (en) Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
BR112019003307A2 (pt) anticorpo ou seu fragmento de ligação a antígeno, capaz de se conectar a um receptor humano de interleucina-6
MX2020007986A (es) Anticuerpos humanizados y desinmunizados.
MX2021000235A (es) Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.
MY165105A (en) Humanized antibody against amyloid beta
BR112022002142A2 (pt) Anticorpos anti-bdca-2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS AG (DE)

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS N.V. (DE)